source
- AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancerThe approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significant…BioSpace · 1h ago↗ source
- An administrative gap delays access to new pancreatic cancer treatmentA new wave of illegal fruity vapes, more and more kids on GLP-1s, and other health news from Morning RoundsSTAT · 2h ago↗ source
- Inhibrx targets OX40 agonist-cancer vaccine studies from early next yearInhibrx Biosciences says its latest mid-stage results show the potential of its OX40 agonist in immunogenic cancers — but also its prospects in combination with cancer vaccines in tumors with lower…